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3At a Glance Commentary
Scientific knowledge on the subject: Bronchiectasis is associated with chronic 
bacterial infection and neutrophilic inflammation. The underlying pathogenesis of 
the disease is poorly understood. Patients with chronic neutrophil inflammation 
have impaired innate and adaptive immunity but the mechanisms by which 
neutrophilic inflammation links to impaired responses to infection are poorly 
characterized. In a proteomic study we identified pregnancy zone protein (PZP), 
previously identified in the serum of pregnant females, in the airway of patients 
with severe bronchiectasis and Pseudomonas aeruginosa infection. PZP is a 
powerful T-cell immunosuppressant thought to prevent rejection of the fetal 
allograft during pregnancy. We hypothesized that PZP may be associated with 
airway infection susceptibility in bronchiectasis. In this study we aimed to 
determine the source of PZP release in the airway and its association with chronic 
infection, airway inflammation and disease severity.
What this study adds to the field: We demonstrate for the first time that elevated 
airway levels of PZP are associated with disease severity, frequent exacerbations 
and airway infection in patients with bronchiectasis. PZP was found in the 
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4cytoplasm of neutrophils and was released during acute and chronic pulmonary 
inflammation. In-vitro, PZP was found to be associated with neutrophil extracellular 
traps (NETS) and in-vivo correlated with NETs detected in bronchiectasis patient 
sputum. Our findings implicate NETosis in the pathophysiology of bronchiectasis 
and given its known immunosuppressive effects, PZP may therefore provide a novel 
link between chronic neutrophilic inflammation and impaired host immunity to 
infection. 
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5Abstract
Background: Pregnancy zone protein (PZP) is a broad-spectrum 
immunosuppressive protein believed to suppress T-cell function during pregnancy 
to prevent fetal rejection. It has not previously been reported in the airway.
Objectives: To characterise PZP in the bronchiectasis airway including its 
relationship with disease severity.
Methods: Label free liquid chromatography/mass spectrometry was performed 
for sputum protein profiling between HRCT confirmed bronchiectasis patients 
with and without P. aeruginosa infection.  Sputum and serum PZP was measured 
by validated ELISA. Airway infection status was established by culture and 16S 
rRNA sequencing. Immunofluorescence, ELISA and electron microscopy was used 
to identify the cellular source of PZP in neutrophils treated with multiple stimuli. 
Results: Elevated PZP was identified by LC/MS as being associated with P. 
aeruginosa infection. In a validation study of 124 patients, sputum, but not serum 
levels of PZP were significantly associated with the bronchiectasis severity index, 
the frequency of exacerbations and symptoms. Airway infection with 
Proteobacteria such as P. aeruginosa was associated with higher levels of PZP. 
PZP in sputum was directly related to airway bacterial load. Neutrophils induced 
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6to form neutrophil extracellular traps (NETs) with phorbol myristate acetate 
(PMA) released high concentrations of PZP in-vitro, and fluorescence microscopy 
confirmed the presence of PZP in NETs, while fluorescence and electron 
microscopy localised PZP to the cytoplasm and nuclei of neutrophils. Effective 
antibiotic therapy reduced sputum PZP. 
Conclusion: PZP is released into NETs. We report a novel link between airway 
infection, NET formation and disease severity in bronchiectasis during chronic 
airway inflammation.  
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7Introduction
Bronchiectasis is a chronic respiratory disease characterised by lung 
inflammation, impaired mucociliary clearance and recurrent airway infection 
leading to permanent tissue destruction and airway dilatation. There is no 
licensed treatment for bronchiectasis and therapeutic development has been 
severely limited by our poor understanding of the pathogenesis of the disease(1).  
Bronchiectasis is a heterogeneous disease in terms of aetiology, inflammatory 
profile, patient characteristics, co-morbidities and background treatments. 
Bronchiectasis is a global health problem and further heterogeneity is added by 
differences in the above factors between different geographical regions (2-4). An 
apparent paradox in bronchiectasis is the persistence of pathogens in the airway 
despite the presence of a robust inflammatory response. During acute 
inflammation with Gram-negative pathogens such as Pseudomonas aeruginosa or 
Gram-positive pathogens such as Staphylococcus aureus, neutrophil recruitment 
is followed by phagocytosis of pathogens and clearance of both bacteria and 
neutrophils through apoptosis and efferocytosis by macrophages. During chronic 
inflammation, this process may be impaired with reduced phagocytosis, reduced 
neutrophil apoptosis and a switch to tolerance and containment of infection 
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8through neutrophil extracellular trap (NET) formation. The mechanisms leading to 
this immunological tolerance remain largely unexplored in bronchiectasis(5). 
Pregnancy zone protein (PZP) is a high molecular weight glycoprotein which was 
originally described as being elevated in the serum of women during 
pregnancy(6). The synthesis of PZP is oestrogen dependent and it is detectable in 
serum a few weeks post-conception and is reported to return to near 
undetectable levels immediately postpartum(7). PZP is a broad spectrum 
immunosuppressant(8) with anti-proteinase activity. Its role in pregnancy is 
thought to be suppression of cell mediated immunoreactivity(9, 10) to prevent 
rejection of the fetus. PZP has been shown to depress T-lymphocyte 
immunoreactivity, T-cell recruitment, migration, proliferation and IL-2 
production(9). These immunosuppressive effects are profound, illustrated by a 
study showing that intravenous infusion of PZP was sufficient to prevent rejection 
of heart allografts in mice(11). Recent experiments using PZP knockout mice have 
shown that PZP also increases susceptibility to viral infection (12). PZP has, 
however, never been previously found in the lung or studied in the context of 
chronic respiratory disease.
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severity and poor outcomes in bronchiectasis. We therefore performed a 
proteomic study to profile sputum from patients with bronchiectasis and P. 
aeruginosa infection compared to those without chronic P. aeruginosa infection. 
Unexpectedly, PZP was identified as being elevated in patients with P. aeruginosa 
infection. We therefore hypothesised that, given the established 
immunosuppressive role of PZP, elevated sputum PZP would be associated with 
increased susceptibility to chronic airway infection and more severe disease. 
Our results demonstrate for the first time that PZP is released from neutrophils 
during degranulation and NET formation. PZP is associated with airway infection 
in bronchiectasis patients and may be an unexpected mechanism through which 
NETs modulate T cell function leading to increased susceptibility to respiratory 
infection.
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Methods
For detailed methods please refer to the online supplement. 
Patients and clinical assessments
Patients were recruited at a specialist bronchiectasis clinic at Ninewells Hospital, 
Dundee, UK. Inclusion criteria were: age ≥ 18 years, bronchiectasis confirmed by 
high resolution CT scan, chronic expectoration with ability to provide a sputum 
sample at the study visit and providing written informed consent. Exclusion 
criteria were: bronchiectasis due to cystic fibrosis, active allergic 
bronchopulmonary aspergillosis, active non-tuberculous mycobacterial infection, 
chronic use of oral corticosteroids, a primary clinical diagnosis of another 
respiratory disease (COPD or asthma) and inability to provide informed consent.  
Ethical approval for the study was given by the East of Scotland Research Ethics 
Committee, approval number 12/ES/0059.
Severity of disease was evaluated using the bronchiectasis severity index (BSI), as 
previously described(13). Exacerbations were defined as administration of 
antibiotics for increasing respiratory symptoms as defined by the British Thoracic 
Society(14). Sputum was obtained from all subjects during a period of clinical 
stability and split into whole (unprocessed) sputum for microbiology and sputum 
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which was diluted 1:8 with PBS and then centrifuged at 3000g for 15 minutes at 
4oC. All sputum processing took place within 2 hours of expectoration and freeze-
thaw cycles were avoided. 
Sputum protein profiling
Sputum protein profiling was performed using nano-flow LC-MS/MS as previously 
described (15).  
Protein identification and label-free quantification were carried out using 
Maxquant (version 1.4.1.2) against Uniprot-human database (version 2014-07-
09). FDR for protein identification was set to 1% at protein level. Data 
visualisation was carried out using SIMCA P (version 13.0.3). For statistical 
analysis, the dataset was log2 transformed before subjecting to t test using 
Perseus (version 1.5.4.1). The Benjamini-Hochberg false discovery rate method 
was used and corrected p values of p<0.05 is considered significant.
Pregnancy zone protein ELISA
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PZP was measured using a commercial ELISA kit for Human and Mouse (Cloud-
Clone Corp). Validation was performed according to published 
recommendations(16). 
Quantification of sputum NETs
Measurement of histone-elastase and DNA-elastase complexes provide a semi-
quantitative assessment of neutrophil extracellular traps in sputum and assays 
were performed as previously described(17). 
Leukocyte studies in healthy volunteers
Neutrophils and peripheral blood monocytes were isolated from healthy 
volunteers using Percoll Gradient Density Centrifugation as previously 
described(18). 
Immunofluorescence was used to confirm and localize PZP within neutrophils and 
NETs and identify co-localisation with other neutrophil proteins. NET formation 
was induced by treatment for 4 hours with 600nM PMA.
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Co-localisation of PZP with neutrophil granule proteins was quantified using 
Manders overlap coefficient which calculates the proportion of overlap of each 
channel with the other, with a value of 1 indicating perfect co-localization and 0 
indicating no co-localization.   
Electron microscopy was used to identify the cellular location of PZP after staining 
with anti-PZP antibody and nanogold secondary. Appropriate negative controls 
were included. 
Murine model of acute inflammation
Female 10-12 week-old C57/B6 mice were infected with S. aureus strain RN6390 at 
an infecting dose of 3 x 108 cfu. At 24 hours post infection the trachea was carefully 
dissected, intubated and bronchoalveolar lavage performed with 3 x 0.4ml PBS. BAL 
supernatant was used for PZP quantification and cells for cytospins to quantify 
neutrophils. 
Sputum bacteriology
Quantitative bacterial culture was performed as described in the supplementary 
material. 
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Microbiota sequencing
PCR and sequencing of the 16S rRNA gene was performed on an Illumina MiSeq as 
previously described(17). Analysis was performed in QIIME (detailed method in 
supplemental information). Alpha diversity was evaluated using the Shannon-
Wiener diversity index and the Berger Parker Index. To compare groups patients 
were split into those with predominant (>50% OTUs) Proteobacteria and those 
with predominant Firmicutes at the phylum level as previously described. 
Antibiotic response study
Patients were asked to attend the research centre if they developed symptoms of 
an exacerbation. Patients were reviewed by a physician and those who were 
prescribed antibiotics for a protocol defined exacerbation were included in the 
study. Patients received treatment for 14 days based on their previous sputum 
microbiology. Spontaneous sputum samples obtained as baseline and after 14 
days were used for PZP measurement. 
COPD cohort study
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To compare sputum PZP levels in bronchiectasis to those from patients with 
COPD, 40 patients with COPD without underlying bronchiectasis were enrolled 
while clinically stable (4 weeks free from antibiotic or corticosteroid therapy). 
Spontaneous sputum samples were obtained and processed in the same way as 
the bronchiectasis samples with sputum PZP and sputum NETs measured by 
ELISA. 
Statistical analysis
Statistical analysis was performed using Graphpad Prism version 8. Categorical 
variables are presented by frequencies and percentages and statistical differences 
were analysed using χ2 test or Fisher exact test when required. Continuous 
variables are presented as mean and standard deviation (SD) or median and 
interquartile range (IQR) when data are not normally distributed. Sputum PZP was 
not normally distributed and so data were log transformed and then analysed 
using t-test for comparisons of two groups and one way ANOVA for more than 
two groups. Paired t-test was used to compare changes in sputum PZP with 
antibiotic therapy. Linear variables were correlated by Spearman correlation. 
Principal component analysis (with the dataset log transformed, mean-centred 
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and unit variance scaled) was performed using SIMCA-P (Version 13.0.3, 
Umetrics). We defined statistical significance as a two-tailed p<0.05 for all 
analyses.
Results
Sputum protein profiling was carried out in 20 bronchiectasis patients (9 with P. 
aeruginosa infection and 11 without) to explore potential biomarkers relevant to 
disease severity in bronchiectasis. Characteristics of the patients included are 
shown in Supplement (Table S1).  Principle component analysis of sputum protein 
profiles reveals two distinct clusters where sputum profiles of patients with P. 
aeruginosa are well separated from those without (Figure 1A).  A total of 80 
proteins were found to be significantly associated with P. aeruginosa in sputum. 
Among differentially expressed proteins many were previously identified 
biomarkers of bronchiectasis lung disease including neutrophil elastase, 
myeloperoxidase, S100-A8 and S100-A9 as shown in the loadings plot (Figure 
1B).We identified pregnancy zone protein (PZP), not previously described as 
present in sputum or as a neutrophil associated protein, to be differentially 
expressed between samples with P. aeruginosa infection and those without. 
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Direct comparison of PZP in the P. aeruginosa infected and uninfected groups is 
shown in figure S1 online. The raw proteomics dataset has been uploaded as 
supplementary Table S4. We therefore explored whether PZP was associated with 
neutrophilic inflammation and bronchiectasis disease severity.
Patient cohort
124 patients were included in the study. There was a slight female predominance 
and a mean age of 67 years typical of European bronchiectasis cohorts (19-21). 
The clinical characteristics of our cohort are shown in Table 1. 
Association of sputum PZP with disease severity in bronchiectasis
Median serum levels of PZP were 4.1 µg/ml (interquartile range 2.2-9.9), 
consistent with published data describing levels expected in healthy men and 
women ((<10 µg/ml in men and postmenopausal women, 10-30 µg/ml in 
premenopausal women(22, 23)).  The median sputum level was 65.9 µg/ml 
(interquartile range 36.9-205.8). There was no significant difference in sputum 
PZP between male and female patients, median 65 µg/ml (IQR 39.1-215) vs 66.8 
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(IQR 34.7-198.5) µg/ml (p=0.8). There was no significant correlation between 
serum and sputum PZP levels (see the online supplement Figure S2).
Using the validated BSI we observed a clear relationship between sputum PZP and 
bronchiectasis severity. There was a significant elevated median sputum PZP in  
patients with severe disease was 163 µg/ml (IQR 64.6-854.1) compared to  mild 
58.6µg/ml (IQR 25.3-163.8), or moderate  disease 52.6 (IQR 24.1-97.3), (Figure 
2A) (p<0.001). It was observed that sputum PZP levels were not normally 
distributed and so data are displayed as log10 values. 
Sputum PZP was also higher in patients with frequent exacerbations (≥3/year) 
compared to patients with less frequent exacerbations, as shown in figure 2B. 
Relationships were also observed with quality of life using the Quality of Life 
Bronchiectasis (QoL-B) Respiratory Symptom Score (p<0.0001) and a weaker 
association was observed with FEV1 % predicted (r=-0.21, p=0.02). Patients with 
higher PZP sputum levels also had a higher daily sputum volume (r=0.2, p=0.02), 
while hospitalization for a severe exacerbation was also predicted by higher 
sputum PZP (p<0.0001). No significant associations were observed between 
serum PZP and severity of disease (online supplement, figure S3) 
C D
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PZP is a marker of airway chronic infection
Airway infection is linked to disease severity and we next validated the previous 
observation that PZP levels are higher in patients with chronic airway infection. 
Using standard microbial culture the most frequently isolated pathogens were H. 
influenzae (n=29) and P. aeruginosa (n=16). Overall 75 patients had chronic 
infection with pathogens while 49 did not. As shown in Figure 3A, patients with P. 
aeruginosa infection had significantly higher levels of sputum PZP compared to 
patients with no growth of pathogens. H. influenzae, Moraxella catarrhalis and 
Enterobacteriaceae were also associated with higher levels of sputum PZP.
When bacterial diversity was assessed by 16S rRNA sequencing we observed no 
relationship between sputum PZP and alpha-diversity using either the Shannon 
diversity index or the Berger-Parker index. PZP levels were, however, significantly 
different in patients with different microbiota profiles at the phylum level – with 
those with Proteobacteria dysbiosis (defined as >50% reads) having significantly 
higher sputum PZP (p=0.01, figure 3B). Patients with PZP levels above the median 
of the population had a higher average % of OTUs classified as Pseudomonas and 
lower % of OTUs classified as Streptococcus and Veillonella (Figure 3C). 
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Sputum PZP is related to airway bacterial load and is reduced by antibiotic 
therapy 
Bacterial load was quantified in 60 patients with bronchiectasis. The 
characteristics of this subgroup are shown in the online supplement (table S2). 
PZP levels were significantly associated with increased bacterial load (p<0.0001 by 
ANOVA, figure 4A). Significant differences were observed between those with 
bacterial loads above 10(7) and all other subgroups (p<0.05 for all pairwise 
comparisons). Excluding patients infected with P. aeruginosa resulted in similar 
results (figure S4 online).
Reduction in bacterial load with antibiotic treatment of exacerbations was 
associated with reduced sputum PZP levels. 20 patients were treated, of which 18 
had detectable bacterial loads at baseline. Figure 4B shows the changes in sputum 
PZP from baseline to end of treatment after 14 days. PZP was significantly 
reduced (p=0.0014 by paired t-test). 6 patients, 5 of whom had P. aeruginosa 
infection, had detectable bacterial loads despite 14 days of antibiotics. Those 
patients who remained culture positive after 14 days had higher PZP at the end of 
treatment compared to those that achieved bacterial clearance (p=0.01, figure 
4C).  Taken together these data show that PZP increases with increasing bacterial 
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load regardless of the infecting pathogen, and that reducing bacterial load with 
antibiotic therapy reduces sputum PZP.  
PZP is released from neutrophils during activation and acute infection
We next examined the potential source of PZP detected in the bronchiectasis 
airway. There was no detectable PZP in the supernatant or cell lysates of primary 
human bronchial epithelial cells. Mononuclear cells released small amounts of 
PZP into the supernatant, mean 46.7ng/ml (SD 18.2, n=4), with higher levels on 
stimulation with 2.5ng/ml PMA (mean 177.8ng/ml, SD 6.4, n=4). Neutrophils 
secreted large amounts of PZP when stimulated with fMLP and PMA (Figure 5A). 
There was a dose-dependent relationship noted with all stimulants. There was 
also PZP released following incubation with bacteria (E.coli and P. aeruginosa) in a 
dose and time dependent manner (figure 5A and Figure S5 online) 
Immunofluorescence by confocal microscopy confirmed the presence of PZP in 
neutrophils (figures 5B and S6+7, supplement video 1+2). Staining was seen in a 
diffuse, punctate pattern throughout the cytoplasm, possibly suggestive of 
granules, however significant co-localisation with other granule proteins 
(neutrophil elastase, lactoferrin, MPO and MMP9) was not observed, Manders 
overlap coefficient <0.3.
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We studied whether acute pulmonary infection, which provokes a neutrophil 
mediated inflammatory response, would result in an increase in PZP in BAL. S. 
aureus was used as a common bronchiectasis pathogen that provokes a robust 
neutrophil response including the formation of NETs. At 24h post infection, S. 
aureus were detected in lung homogenate of infected mice and this was 
associated with BAL neutrophilia. As shown in Figure 5C, infection resulted in an 
increase in PZP in BAL which was directly correlated to BAL neutrophil count. 
PZP is found in the nucleus and cytoplasm of neutrophils and released into 
neutrophil extracellular traps
Based on the observation that PMA, an inducer of NET formation, was a strong 
stimulus for PZP release from neutrophils we hypothesised that PZP may be a 
marker of NETosis. In-vivo in bronchiectasis sputum we identified a strong 
correlation between PZP in sputum and NETs measured by histone-elastase or 
DNA-elastase complexes (Figure 6A). Experimentally induced NETs from healthy 
control neutrophils, treated with PMA, showed staining for PZP in association 
with DNA and neutrophil elastase in a “studded” pattern typical of neutrophil 
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extracellular traps (figure 6B). To further investigate the localisation of PZP in 
neutrophils immune electron microscopy was used. This revealed staining within 
the euchromatin of the nuclei and a diffuse cytoplasmic pattern of PZP within the 
neutrophil.  Our granulocyte extraction method produces neutrophil preparations 
that are >95% pure, but may contain small numbers of eosinophils. We 
unexpectedly observed positive staining of eosinophils in a similar pattern to 
neutrophils with cytoplasmic and nuclear staining. 
Bronchiectasis is not alone in causing chronic neutrophilic inflammation of the 
airway. COPD is characterised by variable degrees of both neutrophilic and 
eosinophilic inflammation and neutrophil extracellular traps have been reported 
in the COPD airway. We therefore measured PZP and NETs in sputum from 
patients with COPD during a period of stability and compared these to samples 
obtained from our bronchiectasis cohort. Characteristics of the COPD patients are 
shown in table S3 online. Both PZP and NETs were significantly lower in COPD 
subjects compared to bronchiectasis (figure 7).
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Discussion
This study has identified pregnancy zone protein (PZP), which was previously 
described as a serum protein elevated in the blood of pregnant women, as an 
unexpected component of NETS and which was found to be released into the 
bronchiectasis airway during chronic infection and is elevated in patients with the 
most severe disease and frequent exacerbations. 
We found levels of PZP in sputum at least 10x higher than levels in serum, 
suggestive of local production by inflammatory cells in the airway. It is known that 
patients with more severe bronchiectasis have higher levels of airway neutrophilic 
inflammation(24) including markers such as neutrophil elastase(25), matrix 
metalloproteinases (26, 27) and cathelicidin(28). PZP followed a similar pattern 
with clear associations with the multidimensional BSI, a higher level in the 
“frequent exacerbator phenotype” and an association with respiratory symptoms. 
The major driver of airway neutrophilic inflammation in bronchiectasis is bacterial 
infection according to the vicious vortex concept of bronchiectasis 
pathophysiology. We demonstrate that PZP is increased in patients with chronic 
infection particularly with P. aeruginosa and H. influenzae, both frequent 
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pathogens in this disease. Molecular “microbiome” based analysis of sputum 
confirmed elevated PZP in patients with Proteobacteria dysbiosis and airway 
dominance of Pseudomonas. This correlates with the clinically observed 
phenotypes that patients who regularly culture Proteobacteria (predominantly 
Pseudomonas and Haemophilus) display clinically more severe phenotypes(29). 
We demonstrate that neutrophils are the likely source of PZP, although in 
common with many immune proteins we found PZP was present in a number of 
cell types including monocytes and eosinophils. PZP appears to be present 
throughout the cytoplasm of neutrophils and is not concentrated within primary 
or secondary granules, it is also consistently visible within the nuclei of both 
neutrophils and eosinophils. We demonstrate in a mouse model of S. aureus 
pneumonia that PZP is released into BAL following infection in parallel with 
neutrophil influx. 
Neutrophils eliminate pathogens through phagocytosis, a relatively non-
inflammatory intracellular process and extracellularly through degranulation. 
Neutrophil extracellular trap formation is a distinct antimicrobial pathway in 
which neutrophils can extrude extracellular DNA, histones and bactericidal 
proteins, intended to trap and neutralise pathogens. Components released in 
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NETs include antimicrobial peptides (lactoferrin, defensins, LL37 and bacterial 
permeability increasing protein); proteases (neutrophil elastase, proteinase 3 and 
gelatinase); and enzymes responsible for reactive oxygen species generation 
(myeloperoxidase). NETs have been described in many chronic diseases including 
chronic respiratory diseases like COPD and cystic fibrosis. It is believed that they 
serve a beneficial role in preventing spread of bacterial infection but also 
contribute to tissue damage.
The identification of PZP in NETs in bronchiectasis is intriguing as it has no known 
antimicrobial effects. The known effects of PZP are as an anti-proteinase and as a 
powerful T-cell immunosuppressant. We speculate PZP may be involved in 
immunological tolerance in bronchiectasis patients by interacting with NETS to 
modulate T-cell functions. The persistence of bacterial infection despite an 
apparently intact cell mediated immune system is a feature of bronchiectasis that 
remains unexplained. It is well established that both Gram-positive and Gram-
negative organisms can induce NET formation and it has been shown that 
neutrophils undergo NET formation in circumstances where phagocytosis is 
prevented, such as with physical barriers preventing phagocytosis as may occur 
with biofilms or with high bacterial loads. We demonstrated a strong association 
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between PZP and elevated airway bacterial load above 107 cfu/g, suggesting that 
NET formation may be the dominant neutrophil phenotype in patients with high 
bacterial loads. Antibiotic therapy was able to reduce PZP levels consistent with a 
cause and effect relationship between bacterial infection and elevated PZP. 
The positive staining of eosinophils in a similar pattern to neutrophils is of 
interest. The inflammation in bronchiectasis is a predominantly neutrophilic 
process but eosinophilic phenotypes do exist. 
Multiple previous reports indicate that PZP is regulated by oestrogens and other 
female reproductive hormones but we found no evidence of a sex based 
difference in serum or sputum PZP levels. Bronchiectasis has a female 
predominance but our evidence suggests PZP is unlikely to play any role in this sex 
disparity. Both male and female patient groups in our cohort are elderly ,it has 
been shown that the physiological fluctuations in estrogen levels affect 
exacerbations and P. aeruginosa mucoid transformation in Cystic Fibrosis(30) but 
such fluctuations will not occur in a predominantly post-menopausal cohort. 
Testosterone has also been shown to affect the antimicrobial susceptibility of P. 
aeruginosa and has established roles in host defence(31). Future studies are 
required to define how sex hormones may be implicated in the pathogenesis of 
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bronchiectasis, but we found no evidence in established disease that PZP was 
associated with sex differences.
In summary, this study has identified a novel neutrophil protein which is released 
predominantly from neutrophil cytoplasm into NETs during chronic inflammation. 
We demonstrate high levels of PZP in the airway in severe disease and patients 
with high bacterial loads. This data suggests for the first time that NETs are 
present in the bronchiectasis airway, are associated with disease severity and 
contain proteins with the potential to have profound effects on the innate and 
adaptive immune system. The validation of this observation in multiple datasets 
using proteomics and ELISA suggests that this finding is robust. Bronchiectasis is a 
heterogeneous disease and there is increasing interest in identifying phenotypes 
and endotypes with distinct clinical outcomes and treatment responses. The 
finding that PZP is a marker of neutrophil mediated inflammation may be 
important for other diseases where neutrophils play a crucial role. Further 
mechanistic work is required to determine whether PZP is simply a marker of 
chronic neutrophilic inflammation or if it has a direct role in the pathogenesis of 
chronic infection in bronchiectasis.
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The strength of this study is the use of multiple methods of clinical assessment 
and two different cohorts to validate our findings, and the confirmation of the 
finding of PZP in neutrophils using multiple methods including ELISA, 
immunofluorescence and electron microscopy. Nevertheless the study has 
limitations. There are no animal models of bronchiectasis and so there is no direct 
method of testing whether PZP is directly involved in the pathogenesis of 
bronchiectasis. We used an acute model of pulmonary inflammation with S. 
aureus because this organism promotes a robust neutrophil mediated response 
but we acknowledge that alternative models such as models of chronic P. 
aeruginosa may provide complementary information. 
In conclusion, this study has identified a novel protein in the bronchiectasis 
airway associated with neutrophil extracellular traps, chronic infection and 
disease severity. 
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Figure legends
Figure 1. Principle component analysis of sputum protein profiles in bronchiectasis. Twenty 
patients with bronchiectasis including 9 with P. aeruginosa infection and 11 without (labelled in 
black) were included. The scores plot based on the first two components is shown in (A) and the 
loadings plot in (B). The cumulative R2X = 0.31 and Q2=0.21. R2X represents the fraction of the 
variation of the X variables explained by the first two components and Q2 indicates the fraction 
of the variation of the X variables predicted by the model. Sputum PZP levels are associated 
with samples with P. aeruginosa infection. 
Figure 2. Association between sputum PZP and clinical outcomes. A: Severity of disease as 
stratified by BSI. B: Exacerbation frequency in previous year. 
Figure 3. Association between sputum PZP and microbiological outcomes. A: Sputum PZP by 
microorganism growth on standard culture. B: Sputum PZP by dysbiosis (defined as >50% reads 
of single phylum on 16S sequencing). C: Patients were divided into those with PZP above and 
below the median value for the population and the %OTU’s compared. The 15 genera most 
strongly associated with lower and 15 genera most strongly associated with higher PZP levels 
are shown. 
Figure 4. Association between bacterial load in sputum and PZP. A: sputum bacterial load is 
associated with sputum PZP (p-value refers to comparison by ANOVA). B: Changes in PZP at the 
start (day 0) and end (day 14) of antibiotic therapy for an acute exacerbation of bronchiectasis. 
The p-value refers to comparison by paired t-test. C: Comparison of patients in (B) who were 
culture positive or culture negative at the end of antibiotic treatment for an exacerbation. p-
value refers to unpaired t-test.
Figure 5. PZP is released from neutrophils in response to fMLP, PMA and bacterial infection in 
mice and humans. A: 107 neutrophils were treated with the indicated stimuli for 30 minutes 
and PZP measured in cell free supernatants. No stimulation control was PBS only. Statistically 
significant differences are obtained using t-test (n=4 biological replicates per condition). B: 10-
12 week C57/B6 mice were infected with S. aureus strain RN6390 (n=18) or PBS control (n=4). 
BAL PZP was measured by ELISA. Significant differences are determined using T-test. 
Association between BAL neutrophils and BAL PZP (n=10 mice undergoing BAL, all infected with 
S. aureus). C: Microscopy image of neutrophils showing DNA: DAPI, Blue, neutrophil elastase: 
Green and Pregnancy zone protein: Red. 
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Figure 6. PZP is a cytoplasmic and nuclear protein which is released in neutrophil extracellular 
traps A: In patients with bronchiectasis, extracellular PZP correlates with markers of neutrophil 
extracellular trap formation B: Peripheral blood neutrophils induced to undergo NET formation 
with 600nM PMA for 4 hours, NETs contain PZP. C: Electron microscopy of neutrophils (left) and 
neutrophils plus eosinophils (right) showing diffuse cytoplasmic and nuclear staining for PZP 
(black dots).
Figure 7. A) PZP levels in sputum in patients with bronchiectasis N=124 or COPD N=40 B) 
Neutrophil extracellular traps measured using the histone-elastase complex assay in 
bronchiectasis and COPD. For both assays comparisons are by t-test.
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Table 1. Patient characteristics. Abbreviations: BSI= bronchiectasis severity index, FEV1= Forced 
expiratory volume in 1 second, COPD = Chronic Obstructive Pulmonary Disease, ABPA = Allergic 
Bronchopulmonary Aspergillosis (* these patients had previously treated ABPA, rather than 
active disease), PCD= Primary ciliary dyskinesia, GORD = Gastro-oesophageal reflux disease. 
N 124
Mean age (standard deviation- SD) 69.1 (10.7)
% female 53.2%
Mean BSI (SD) 7.8 (4.2)
No. Mild 30 (24.2%)
No. Moderate 56 (45.2%)
No. Severe 38 (30.6%)
Mean exacerbation frequency/ year (SD) 2.6 (2.1)
Mean FEV1 (% predicted) 78.1% (25.5)
Aetiology
Idiopathic 82 (66.1%)
COPD 16 (12.9%)
Post-infective 8 (6.5%)
Inflammatory Bowel 
Disease
4 (3.2%)
Immunodeficiency 3 (2.4%)
ABPA* 2 (1.6%)
Rheumatoid Arthritis 2 (1.6%)
PCD 1 (0.8%)
Aspiration 1 (0.8%)
Youngs syndrome 1 (0.8%)
Asthma 1 (0.8%)
GORD 1 (0.8%)
Haematological 
malignancy
1 (0.8%)
Other 1 (0.8%)
Smoking
Current 12 (9.7%)
Ex 52 (41.9%)
Never 60 (48.4%)
Antibiotics
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Long term 
macrolides
27 (21.8%)
Inhaled 5 (4%)
Page 36 of 62 AJRCCM Articles in Press. Published on 02-July-2019 as 10.1164/rccm.201812-2351OC 
 Copyright © 2019 by the American Thoracic Society 
 Figure 1. Principle component analysis of sputum protein profiles in bronchiectasis. Twenty patients with 
bronchiectasis including 9 with P. aeruginosa infection and 11 without (labelled in black) were included. The 
scores plot based on the first two components is shown in (A) and the loadings plot in (B). The cumulative 
R2X = 0.31 and Q2=0.21. R2X represents the fraction of the variation of the X variables explained by the 
first two components and Q2 indicates the fraction of the variation of the X variables predicted by the 
model. Sputum PZP levels are associated with samples with P. aeruginosa infection. 
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 Figure 2. Association between sputum PZP and clinical outcomes. A: Severity of disease as stratified by BSI. 
B: Exacerbation frequency in previous year. 
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 Figure 3. Association between sputum PZP and microbiological outcomes. A: Sputum PZP by microorganism 
growth on standard culture. B: Sputum PZP by dysbiosis (defined as >50% reads of single phylum on 16S 
sequencing). C: Patients were divided into those with PZP above and below the median value for the 
population and the %OTU’s compared. The 15 genera most strongly associated with lower and 15 genera 
most strongly associated with higher PZP levels are shown. 
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 Figure 4. Association between bacterial load in sputum and PZP. A: sputum bacterial load is associated with 
sputum PZP (p-value refers to comparison by ANOVA). B: Changes in PZP at the start (day 0) and end (day 
14) of antibiotic therapy for an acute exacerbation of bronchiectasis. The p-value refers to comparison by 
paired t-test. C: Comparison of patients in (B) who were culture positive or culture negative at the end of 
antibiotic treatment for an exacerbation. p-value refers to unpaired t-test. 
265x81mm (300 x 300 DPI) 
Page 40 of 62 AJRCCM Articles in Press. Published on 02-July-2019 as 10.1164/rccm.201812-2351OC 
 Copyright © 2019 by the American Thoracic Society 
 Figure 5. PZP is released from neutrophils in response to fMLP, PMA and bacterial infection in mice and 
humans. A: 107 neutrophils were treated with the indicated stimuli for 30 minutes and PZP measured in cell 
free supernatants. No stimulation control was PBS only. Statistically significant differences are obtained 
using t-test (n=4 biological replicates per condition). B: 10-12 week C57/B6 mice were infected with S. 
aureus strain RN6390 (n=18) or PBS control (n=4). BAL PZP was measured by ELISA. Significant differences 
are determined using T-test. Association between BAL neutrophils and BAL PZP (n=10 mice undergoing BAL, 
all infected with S. aureus). C: Microscopy image of neutrophils showing DNA: DAPI, Blue, neutrophil 
elastase: Green and Pregnancy zone protein: Red. 
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 Figure 7. A) PZP levels in sputum in patients with bronchiectasis N=124 or COPD N=40 B) Neutrophil 
extracellular traps measured using the histone-elastase complex assay in bronchiectasis and COPD. For both 
assays comparisons are by t-test. 
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Supplementary results
Pseudomonas, n=9 Non-Pseudomonas, n=11
Age (mean) 63 66.91
Sex 66.6% female (n=6) 54.5% female (n=6)
SGRQ score 57.8 45.25
Previous hospitalisations 
(mean)
0.89 0.27
Exacerbations since last 
visit (mean)
4.78 1.91
MRC dyspnoea score 3.11 1.91
Table S1. Characteristics of the patients in original proteomics screening study. 
Figure S1 Comparison of Pseudomonas and Non-Pseudomonas groups in original 
proteomics screen (p=0.007)
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Figure S2 - A, Serum PZP in male and female patients (error bars show mean with 
SEM); B Sputum PZP in Male and Female patients (error bars show Mean and 
SEM); C, Correlation between serum and sputum PZP (p=0.07).
Figure S3  . Serum pregnancy zone protein and the bronchiectasis severity index. 
No relationship was observed between PZP and BSI (p=0.15 by ANOVA). 
Variable N (%) or mean (SD)
N 20
Mean Age 62 (12.5)
Sex 60% female
Mean FEV1 (% predicted) 60.77% (21.38)
Mean BSI 11.95 (4.53)
A B C
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Organism cultured
P. aeruginosa 8 (40%)
H. influenzae 4 (20%)
E. coli 1 (5%)
M. catarrhalis 1 (5%)
H. parainfluenzae 1 (5%)
S. maltophilia 1 (5%)
Achromobacter 1 (5%)
Enterobacter 1(5%)
Mixed flora 2(10%)
Table S2. Characteristics of the bacterial load study participants
Figure S4. The relationship between bacterial load and sputum PZP excluding 
patients with P. aeruginosa infection. The difference across the groups is 
statistically significant by ANOVA p<0.0001. 
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Figure S5. Release of PZP following P. aeruginosa infection. 10(6) neutrophils per 
time point were infected at a multiplicity of infection of 1:10. Following 
centrifugation to remove bacteria and neutrophils, PZP was measured in 
supernatant by ELISA. Results are the mean of 3 biological replicates.
Figure S6 Microscopy image of neutrophils showing DNA: DAPI, Blue, MMP-9: 
Green and Pregnancy zone protein: Red. 
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Figure S7 Microscopy image of neutrophils showing DNA: DAPI, Blue, MPO: Green 
and Pregnancy zone protein: Red. 
Video S1 – 3D video of neutrophils stained for PZP and MMP9
Video S2 – 3D video of neutrophils stained for PZP and MPO
N=40
Mean Age (SD) 72.5 (8.72)
Sex 66.67% male
Mean FEV1 (% predicted)(SD) 68.78% (20)
 Table S3. COPD study patient characteristics
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Figure S8.  No effect of pregnancy zone protein at physiological concentrations on 
ciliary beat frequency (n=3 replicates from different donors, n=8 observations per 
donor). No significant differences were observed. Right shows no statistically 
significant difference in neutrophil phagocytosis after exposure to physiological 
doses of pregnancy zone protein (N=3 biological replicates from different donors, 
p=0.11). 
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Supplementary methods
Patients and clinical assessments
Patients were recruited at a specialist Bronchiectasis clinic at Ninewells Hospital, 
Dundee, UK. Inclusion criteria were: age > 18 years, bronchiectasis confirmed by 
high resolution CT scan, chronic expectoration with ability to provide a sputum 
sample at the study visit and providing written informed consent. Exclusion 
criteria were: bronchiectasis due to cystic fibrosis, active allergic 
bronchopulmonary aspergillosis, active non-tuberculous mycobacterial infection, 
chronic use of oral corticosteroids and inability to provide informed consent.  
Ethical approval for the study was given by the East of Scotland Research Ethics 
Committee, approval number 12/ES/0059.
Patients underwent clinical evaluation including microbiology (described below), 
assessment of severity of disease using the bronchiectasis severity index, as 
previously described(13), and recording of exacerbation frequency. Exacerbations 
were defined as administration of antibiotics for increasing respiratory symptoms 
as defined by the British Thoracic Society(14). Sputum was obtained from all 
subjects during a period of clinical stability and split into whole (unprocessed) 
sputum for microbiology and sputum which was diluted 1:8 with PBS and then 
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centrifuged at 3000g for 15 minutes at 4oC . All sputum processing took place 
within 2 hours of expectoration and freeze thaw cycles were avoided. The 
supernatant was stored at -80oC until analysis.
Sputum protein profiling
Protein concentrations of sputum supernatants were quantified using Pierce 660 
protein assay. Fifty micrograms of sputum protein from each sample was added 
to an equal volume of acetonitrile before incubating at 100°C for 15 min. The 
samples were dried down in a centrifugal vacuum and resuspended with 50mM 
ammonium bicarbonate (pH8.5) to a final concentration of 1 mg/ml. Samples 
were then reduced and alkylated before subjecting to nano-flow-LC-MS/MS 
analysis according to the previous report(15).  
Protein identification and label-free quantification were carried out using 
Maxquant (version 1.4.1.2) against Uniprot-human database (version 2014-07-
09). The fixed modification was carbamidomethylation on cysteine, and variable 
modifications include oxidation on methionine and N-terminal acetylation. FDR 
for protein identification was set to 1% at protein level. Data visualisation was 
carried out using SIMCA P (version 13.0.3). For statistical analysis, the dataset was 
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log2 transformed before subjecting to t test using Perseus (version 1.5.4.1). The 
Benjamini-Hochberg false discovery rate method was used and corrected p values 
of p<0.05 is considered significant.
Pregnancy zone protein ELISA
PZP was measured using a commercial ELISA kit (Cloud-Clone Corp., SEG324Hu 
and SEG324Mu). Validation was performed according to published 
recommendations(16). The optimal dilutions were 1:100,000 for sputum and 
1:500 for serum and 1:5 for murine Broncho-alveolar lavage (BAL) samples.  
All sputum samples used in ELISA were processed within 2 hours of expectoration. 
We confirmed stability of PZP in sputum by incubated sputum at room 
temperature for 48 hours with samples taken at 4, 24 and 48 hours as shown 
below (Figure S9)
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Figure S9. Stability of PZP in sputum over 48 hours. Samples were incubated in the 
laboratory at room temperature and aliquots processed for measurement of PZP 
(as described in the methods) at the indicated time points. No significant 
differences were observed comparing PZP at baseline and after 4 hours at room 
temperature (p=0.8)
Quantification of sputum NETs
Measurement of histone-elastase and DNA-elastase complexes provide a semi-
quantitative assessment of neutrophil extracellular traps in sputum and assays 
were performed as previously described(17). 
Leukocyte studies in healthy volunteers
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Neutrophils and peripheral blood monocytes were isolated from healthy 
volunteers using Percoll Gradient Density Centrifugation as previously 
described(18). Neutrophils and monocytes were stimulated with Phorbol 
myristate acetate (PMA, 0.1-100μg/ml), N-formylmethionine-leucyl-phenylalanine 
(fMLP, 0.1-100μg/ml) and bacteria (Eschericiacoli strain BL21 and P. aeruginosa 
strain PA01, at multiplicity of infection ranging from 10:1 to 1:100. Following 
stimulation neutrophils were centrifuged at 1200g for 5 mins. PZP was measured 
in the resulting supernatant. 
Immunofluorescence was used to confirm and localize PZP within neutrophils and 
NETs and identify co-localisation with other neutrophil proteins. Cells were 
seeded to glass coverslips (2*105 cells per slip) in 500μl RPMI (containing 2% 
human serum), for 1 hour. NET formation was induced by treatment for 4 hours 
with 600nM PMA.
Samples were fixed in 4% paraformaldehyde for 1 hour. Cells were permeabilized 
in 0.5%  Triton X-100 for 1min before blocking with 5% BSA. Cells were labelled 
with primary antibodies, mouse monoclonal antibodies to PZP (Sigma-Aldrich 
HPA041471) and a rabbit polyclonal antibody to one of the following: neutrophil 
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elastase(R&D MAB91671), matrix metallopeptidase 9 (MMP9) (Thermo-Fisher 
MA5-14228), lactoferrin (Thermo-Fisher MA5-18107) or myeloperoxidase (MPO) 
(Thermo-Fisher MA1-80878) followed by appropriate secondary antibodies (goat 
anti mouse Alexafluor 488 and goat anti rabbit Alexafluor 594). Samples were 
stained with DAPI, mounted on clean glass slides and observed by confocal 
microscopy (Leica TCS SP5). Co-localisation of PZP with neutrophil granule 
proteins was quantified using Manders overlap coefficient which calculates the 
proportion of overlap of each channel with the other, with a value of 1 indicating 
perfect colocalization and 0 indicating no colocalization.   
Electron Microscopy
Granulocytes isolated by Percoll gradient were fixed in 4% paraformaldehyde, 
suspended in an agar pellet and stored in 30% wt/vol sucrose until use. Cell 
pellets were frozen in cryomoulds using OCT(Tissue-Tek). 10µm cryosections were 
cut, blocked with BSA and labelled with anti-PZP antibody (Sigma-Aldrich 
HPA041471). To visualise the location of PZP by electron microscopy cells were 
labelled with a nanogold secondary (rabbit anti goat 1:200, EMS) followed by gold 
enhancement for 20mins (Universal Biologics 2114) 
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Labelled sections were fixed in 2.5% glutaraldehyde, post fixed in osmium 
tetroxide, dehydrated using a gradient of ethanols (70%, 90% and 100%) and 
embedded in araldite. 70nm sections were cut using an ultramicrotome (ultracut 
E, Leica) and stained post embedding using heavy metals (Uranyl acetate and lead 
citrate). Cells were visualised on a transmission electron microscope (Jeol 1400+) 
using a digital 4kX4k camera (AMT 16X, Deben Ltd, UK), appropriate negative 
controls were conducted.
Murine model of acute inflammation
In-vivo procedures were conducted according to the requirements of the United 
Kingdom Home Office Animals Scientific Procedures Act, 1986 and approved by the 
University of Dundee ethical review committee. Female 10-12 week old C57/B6 
mice. S. aureus strain RN6390 was subcultured at 1:100 dilution from an overnight 
culture into fresh TSB medium. Cells were grown at 37°C with shaking until an OD600 
of 0.5 was reached, before harvesting and washing three times in 1x PBS. Cells were 
finally resuspended in 1 x PBS. Mice were anaesthetized and infected intranasally 
with 25 µl of the bacterial suspension at an infecting dose of 3 x 108 cfu. At 24 hours 
post infection the trachea was carefully dissected, intubated and bronchoalveolar 
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lavage performed with 3 x 0.4ml PBS. BAL was centrifuged at 1300 rpm for minutes 
at 4oC.  Supernatant was stored at -80oC and the cell pellet resuspended in 110µl 
media containing serum.  10μl cells were mixed with 10μl trypan blue and counted 
on a haemocytometer.  Cytospins were prepared and stained for differential cell 
counts using Wright-Giemsa staining kit. Murine PZP was measured using ELISA. 
Sputum bacteriology
Quantitative bacterial culture was performed on sputum samples within 4 hours 
of expectoration. Sputum was homogenized in 50:50 volume 0.1% dithiothreitol 
and serially diluted in sterile 0.9% sodium chloride for plating on blood agar and 
choclate with bacitracin agar. Plates were inoculated with 100ul of diluted sample 
and colony forming units of each identified pathogen counted after 48 hours 
incubation. Bacterial density is expression as log10 cfu/g. 
Microbiota sequencing
The AllPrep DNA/RNA Mini kit was used to extract DNA and RNA from whole 
sputum:  Sputum was incubated in an equal volume of 1:10 diluted Sputolysin 
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(Calbiochem) for 30mins at 37°C, mixed with Buffer RLT as per the AllPrep kit 
protocol, then passed through QIAshredder columns (QIAGEN) with the 
supernatant undergoing sequential DNA and RNA extraction. extraction on the 
QIAcube automation platform.   Alternatively, 0.1g whole sputum was incubated 
with Proteinase K for one hour at 55°C then processed as described in Zymo 
Quick-DNA Miniprep Plus solid tissues protocol, eluting into 50μL elution buffer.
We assessed quality and quantity of the DNA and RNA by Nanodrop and Qubit 
machine, using the Qubit dsDNA broad range kit (Thermo Scientific).  
Metagenomic sequencing of the bacterial 16S rRNA gene was performed 
following the protocol in the Illumina library prep guide 
(https://www.illumina.com/content/dam/illumina-
support/documents/documentation/chemistry_documentation/16s/16s-
metagenomic-library-prep-guide-15044223-b.pdf), using primers targeting the V3 
and V4 region.  
Nextera XT Indices were added to each sample to allow multiplexing and the 
libraries sequenced using 2 x 300 paired end sequencing on the MiSeq platform 
using a MiSeq V3 kit (Illumina).  Following sequencing, FastQ files were imported 
into QIIME (version 1.9.0) and quality of reads checked. Any reads with a Phred 
quality score less than Q20 were excluded when paired end reads were joined 
Page 59 of 62  AJRCCM Articles in Press. Published on 02-July-2019 as 10.1164/rccm.201812-2351OC 
 Copyright © 2019 by the American Thoracic Society 
together for each sample. Un-joined reads were excluded from subsequent 
analysis.  Sequences were clustered into operational taxonomic units (OTUs) 
based on 97% sequence similarity using the UCLUST algorithm , aligned against 
the Greengenes Core reference alignment (Version 13.8) using PyNAST (Version 
1.2.2).  Taxonomy of the OTUs was assigned using the Ribosomal Database 
Project Classifier (Version 2.2) with the de novo OTU picking option (E10).  OTUs 
were examined to remove singletons and unassigned OTUs, or OTUs identified as 
Eukaryota, Human and Cyanobacteria.  The data was normalised to the lowest 
number of OTUs and the Shannon-Wiener Species Diversity Index (SWDI) of the 
samples determined. 
Analysis was performed in QIIME. To compare groups patients were split into 
those with predominant (>50% OTUs) proteobacteria and those with 
predominant firmicutes at the phylum level as previously described. 
Antibiotic response study
Patients were asked to attend the research centre if they developed symptoms of 
an exacerbation. Patients were reviewed by a physician and those who were 
prescribed antibiotics for a protocol defined exacerbation were included in the 
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study. Patients received treatment for 14 days based on their previous sputum 
microbiology. Spontaneous sputum samples obtained as baseline and after 14 
days were used for PZP measurement. 
COPD cohort study
To compare sputum PZP levels in bronchiectasis to those from patients with 
COPD, 40 patients with COPD without underlying bronchiectasis were enrolled 
while clinically stable (4 weeks free from antibiotic or corticosteroid therapy). 
Spontaneous sputum samples were obtained and processed in the same way as 
the bronchiectasis samples with sputum PZP and sputum NETs measured by 
ELISA. 
Neutrophil phagocytosis assay
Was evaluated by flow cytometry on a BD Fortessa. FITC-labelled P. aeruginosa 
strain PA01 were opsonised with 10% serum and incubated with neutrophils 
(multiplicity of infection 10:1) which had been treated with recombinant PZP at 
the indicated concentrations or vehicle control. Phagocytosis was quantified by 
the mean fluorescence after gating on the neutrophil population. 
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Ciliary beat frequency measurement
Primary nasal epithelial cells from healthy donors were obtained by brushing of 
the inferior nasal turbinate followed by culture at air liquid interface. Ciliary 
beating analysis and quantification was performed by high-speed 
videomicroscopy. 
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